Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Publication Name: Annals of Surgical Oncology

Author(s): Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen B, Lee L, Nash C, Gittleman M, Akbari S, Beitsch PD.

PURPOSE: The purpose of the NBRST study is to compare a multigene classifier to conventional immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH) subtyping to predict chemosensitivity as defined by pathological complete response (pCR) or endocrine sensitivity as defined by partial response. … Continued

Molecular subtyping improves stratification of patients into diagnostically more meaningful risk groups

Publication Name: Cancer Research

Author(s): Massimo Cristofanilli, Karen Kaul, Mary Turk, JoEllen Weaver, Jelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Katharine Yao

This retrospective study showed that Molecular Subtyping of early breast cancers using Mammaprint and BluePrint leads to reclassification of 25% (51/208) of tumors with potential therapeutic and prognostic implications: – 39% of clinical HER-2 disease should have been treated with … Continued

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics

Publication Name: Breast Cancer Research and Treatment

Author(s): Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards

It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor a (ERa), but fails to respond to hormonal therapy due to the expression of … Continued

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

Publication Name: Breast Cancer Research and Treatment

Author(s): Stefan Glück, Femke de Snoo, Justine Peeters, Lisette Stork-Sloots, George Somlo

The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and MammaPrint molecular subtyping versus … Continued

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

Publication Name: Annals of Surgical Oncology

Author(s): Bichlien Nguyen, Pino G. Cusumano, Kenneth Deck, Deborah Kerlin, Agustin A. Garcia, Julie L. Barone, Edgardo Rivera, Katharine Yao, Femke A. de Snoo, Jeroen van den Akker, Lisette Stork-Sloots, Daniele Generali

Purpose: To compare breast cancer subtyping with the three centrally assessed microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Methods: BluePrint, MammaPrint, and TargetPrint were all performed on … Continued

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

Publication Name: Breast Cancer Research and Treatment

Author(s): Oscar Krijgsman, Paul Roepman, Wilbert Zwart, Jason S. Carroll, Sun Tian, Femke A. de Snoo, Richard A. Bender, Rene Bernards, Annuska M. Glas

Classification of breast cancer into molecular subtypes maybe important for the proper selection of therapy, as tumors with seemingly similar histopathological features can have strikingly different clinical outcomes. Herein, we report the development of a molecular subtyping profile (BluePrint), that … Continued

A gene profile that identifies molecular subtypes of breast cancer is highly enriched in genes having Estrogen Receptor binding sites

Publication Name: ASCO 2011 Poster

Author(s): W. Zwart, F. De Snoo, et al

Classification of breast cancer into molecular subtypes may be important for the proper selection of therapy, as tumors with seemingly similar biology can have strikingly different clinical outcomes. We have previously developed an 80-gene molecular subtyping profile (BluePrint) for the classification of breast cancer into three … Continued

Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Publication Name: Annals of Oncology

Author(s): A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thu¨ rlimann, H.-J. Senn & Panel

The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these … Continued

Combining multigene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer

Publication Name: Abstract, ASCO 2009

Author(s): Stork-Sloots L, Krijgsman O, Roepman P, et al. Combining multigene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer. J Clin Oncol 2009; 27: 15s

Background: Classification of breast cancers into molecular subtypes may be important for accurate selection of therapy for patients. Herein we report a multigene profile for classification of breast cancer into molecular subtypes. The profile separates tumors into hormone receptor (HR)+/luminal-like, HER2+/ERBB2-like, … Continued